ST LOUIS -- Monsanto announced today that new data from a national study of milk show that marketing claims implying that milk from cows not treated with POSILAC bovine somatotropin (bST) is safer or healthier are misleading.
Scientific analysis of retail milk samples gathered from 48 states showed no difference in concentrations of bST, insulin-like growth factor 1 (IGF-1), progesterone or nutrients in conventionally produced milk and conventionally produced milk labeled as coming from cows not supplemented with POSILAC. No antibiotic residues were found in any samples.
The findings of the study, conducted by Monsanto with third-party testing facilities and an independent auditing firm, reinforce that milk marketing claims differentiating milk based on POSILAC use are meaningless.
"The study findings are not surprising. Marketing claims that imply differences are unsupported by the scientific data," said John Vicini, lead dairy scientist for Monsanto. "The results are consistent with FDA's exhaustive review of previous studies."
The new study included 213 samples of 95 milk brands and compared conventionally produced milk with conventionally produced milk labeled as coming from cows not receiving POSILAC. The samples were gathered from 162 retail locations in 48 states. The study results, which Monsanto intends to submit to a peer-reviewed scientific journal, showed that there was:
- No difference in the levels of the hormones progesterone, IGF-1 or bST,
- No differences in nutrients, and
- No antibiotic residue in any of the samples.
- Monsanto initiated the research after recent actions taken by several processors and retailers implied or suggested to consum